[CAS NO. 2227482-41-7] ELOVL1-IN-1
PRODUCTS SPECIFICATIONS [2227482-41-7]
DESCRIPTION [2227482-41-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 340.33 |
| Molecular Formula | C18H14F2N4O |
| SMILES | O=C(C1(CC1)C2=C(F)C=CC=C2)NC3=NN(C4=CC(F)=NC=C4)C=C3 |
Summary
ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD) [1] .
IC50 & Target
ELOVL1 [1]
In Vitro
ELOVL1-IN-1 (compound 87) (1 nM-10 μM; 48 h) reduces the the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐type (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 100 mg/mL ( 293.83 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.9383 mL | 14.6916 mL | 29.3832 mL |
| 5 mM | 0.5877 mL | 2.9383 mL | 5.8766 mL |
| 10 mM | 0.2938 mL | 1.4692 mL | 2.9383 mL |